NCT00141479View on ClinicalTrials.gov

To Evaluate the Impact of Treatment Interruption on Re-initiation of Bifeprunox

PHASE2CompletedINTERVENTIONAL
Timeline

Start Date

May 31, 2005

Primary Completion Date

November 30, 2006

Study Completion Date

November 30, 2006

Conditions
SchizophreniaSchizoaffective Disorder
Interventions
DRUG

Bifeprunox

Trial Locations (1)

Unknown

Site 1, Wichita

All Listed Sponsors
collaborator

H. Lundbeck A/S

INDUSTRY

collaborator

Wyeth is now a wholly owned subsidiary of Pfizer

INDUSTRY

lead

Solvay Pharmaceuticals

INDUSTRY

NCT00141479 - To Evaluate the Impact of Treatment Interruption on Re-initiation of Bifeprunox | Biotech Hunter | Biotech Hunter